Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Amsterdam
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
49.37(c) 48.35(c) 47.94(c) 49.99(c) 49.81 Last
331 331 350 646 257 078 586 719 82 705 Volume
+3.32% -2.07% -0.85% +4.28% -0.36% Change
More quotes
Estimated financial data (e)
Sales 2021 485 M 549 M 549 M
Net income 2021 -182 M -206 M -206 M
Net cash position 2021 3 976 M 4 504 M 4 504 M
P/E ratio 2021 -18,9x
Yield 2021 -
Sales 2022 510 M 577 M 577 M
Net income 2022 -244 M -277 M -277 M
Net cash position 2022 3 542 M 4 012 M 4 012 M
P/E ratio 2022 -18,0x
Yield 2022 -
Capitalization 3 277 M 3 716 M 3 712 M
EV / Sales 2021 -1,44x
EV / Sales 2022 -0,52x
Nbr of Employees 1 319
Free-Float 74,5%
More Financials
Company
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies... 
More about the company
Ratings of Galapagos NV
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GALAPAGOS NV
01/19GALAPAGOS : JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WIT..
PU
01/18Galapagos Wins Expanded UK Nod for Inflammatory Bowel Disease Drug Jyseleca
MT
01/18Galapagos Gets UK Approval for Jyseleca to Treat Ulcerative Colitis
MT
01/18Jyseleca®▼ (filgotinib) licensed for the treatment of adult patients with moderat..
AQ
01/18Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Ag..
CI
01/14Galapagos Supervisory Board Creates 30,000 Subscription Rights Plan
MT
01/13GALAPAGOS : creates new subscription right plan - Form 6-K
PU
01/13Galapagos creates new subscription right plan
AQ
01/10GALAPAGOS : to present at 40th Annual J.P. Morgan Healthcare Conference - Form 6-K
PU
01/06Morgan Stanley Adjusts Galapagos NV's Price Target to $77 from $118, Keeps Overweight R..
MT
01/06Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
AQ
01/06RBC Cuts Price Target on Galapagos to $63 From $65, Maintains Sector Perform Rating
MT
2021GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
2021Galapagos increases share capital through subscription right exercises
GL
2021Galapagos increases share capital through subscription right exercises
GL
More news
News in other languages on GALAPAGOS NV
01/19Galapagos krijgt groen licht in VK
01/18Galapagos obtient l'aval du Royaume-Uni pour le médicament Jyseleca contre les maladies..
01/18Jyseleca®▼ (filgotinib) krijgt vergunning voor de behandeling van volwassen patië..
01/18Jyseleca®▼ (filgotinib) krijgt vergunning voor de behandeling van volwassen patië..
01/18Galapagos NV annonce l'autorisation de l'Agence de réglementation des médicaments et de..
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 49,99 €
Average target price 55,56 €
Spread / Average Target 11,1%
EPS Revisions
Managers and Directors
Onno van de Stolpe Chief Executive Officer
Bart Filius President & Chief Operating Officer
Raj Bhikhu Parekh Chairman
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV1.56%3 716
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831